{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:00:40Z","timestamp":1778778040390,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.vaccine.2023.06.023","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T12:50:46Z","timestamp":1686833446000},"page":"4422-4430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021\u2013February 2022"],"prefix":"10.1016","volume":"41","author":[{"given":"Emily Jane","family":"Woo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julianne","family":"Gee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0757-4683","authenticated-orcid":false,"given":"James","family":"Baggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winston E.","family":"Abara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-8312","authenticated-orcid":false,"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rositsa B.","family":"Dimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-8031","authenticated-orcid":false,"given":"John R.","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.06.023_b0005","unstructured":"Emergency Use Authorization letter for Janssen COVID-19 Vaccine. https:\/\/www.fda.gov\/media\/146303\/download [accessed 3\/30\/2023]."},{"issue":"9","key":"10.1016\/j.vaccine.2023.06.023_b0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.15585\/mmwr.mm7009e4","article-title":"The advisory committee on immunization practices\u2019 interim recommendation for use of Janssen COVID-19 vaccine\u2014United States, February 2021","volume":"70","author":"Oliver","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.06.023_b0015","unstructured":"Fact Sheet for healthcare providers administering vaccine (Vaccination Providers). Emergency Use Authorization (EUA) of Janssen COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19). https:\/\/www.fda.gov\/media\/146304\/download [accessed 3\/30\/2023]."},{"key":"10.1016\/j.vaccine.2023.06.023_b0020","unstructured":"FDA Briefing Document: Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. https:\/\/www.fda.gov\/media\/146217\/download; [accessed 3\/30\/2023]."},{"key":"10.1016\/j.vaccine.2023.06.023_b0025","series-title":"Pharmacoepidemiology","article-title":"Special methodological issues in pharmacoepidemiology studies of vaccine safety","author":"Chen","year":"2005"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.023_b0030","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) \u2013 United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"issue":"36","key":"10.1016\/j.vaccine.2023.06.023_b0035","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.023_b0040","unstructured":"V-safe After Vaccination Health Checker for COVID-19 Vaccine. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/vsafe.html [accessed 3\/30\/2023]."},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.023_b0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021","volume":"70","author":"Gee","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"18","key":"10.1016\/j.vaccine.2023.06.023_b0050","doi-asserted-by":"crossref","first-page":"680","DOI":"10.15585\/mmwr.mm7018e2","article-title":"Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021","volume":"70","author":"Shay","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"24","key":"10.1016\/j.vaccine.2023.06.023_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.7517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.023_b0060","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2023.06.023_b0065","unstructured":"Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine; https:\/\/www.fda.gov\/news-events\/press-announcements\/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine [accessed 3\/30\/2023]."},{"key":"10.1016\/j.vaccine.2023.06.023_b0070","unstructured":"FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough [accessed 3\/30\/2023]."},{"issue":"16","key":"10.1016\/j.vaccine.2023.06.023_b0075","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jama.2021.16496","article-title":"Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February-July 2021","volume":"326","author":"Woo","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.06.023_b0080","unstructured":"Code of Federal Regulations. 21 600.80."},{"key":"10.1016\/j.vaccine.2023.06.023_b0085","unstructured":"Vaccine Adverse Event Reporting System (VAERS) Standard Operating Procedures for COVID-19. https:\/\/www.cdc.gov\/vaccinesafety\/pdf\/VAERS-v2-SOP.pdf [accessed 3\/30\/2023]."},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.023_b0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.06.023_b0095","unstructured":"Leading Causes of Death. https:\/\/www.cdc.gov\/nchs\/nvss\/leading-causes-of-death.htm [accessed 3\/30\/2023]."},{"key":"10.1016\/j.vaccine.2023.06.023_b0100","unstructured":"COVID Data Tracker. https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations [accessed 3\/30\/2023]."},{"issue":"9","key":"10.1016\/j.vaccine.2023.06.023_b0105","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/infdis\/jiab628","article-title":"Expected rates of select adverse events after immunization for coronavirus disease 2019 vaccine safety monitoring","volume":"225","author":"Abara","year":"2022","journal-title":"J Infect Dis"},{"issue":"28","key":"10.1016\/j.vaccine.2023.06.023_b0110","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.vaccine.2021.05.016","article-title":"Population-based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines","volume":"39","author":"Gubernot","year":"2021","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.vaccine.2023.06.023_b0115","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vaccine.2023.06.023_b0120","series-title":"Statistical methods for rates and proportions","author":"Fleiss","year":"2003"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2023.06.023_b0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.vaccine.2023.06.023_b0130","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/pds.5523","article-title":"Thromboembolic events after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system","volume":"31","author":"Woo","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"31","key":"10.1016\/j.vaccine.2023.06.023_b0135","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1016\/j.vaccine.2022.05.078","article-title":"Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system","volume":"40","author":"Woo","year":"2022","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.023_b0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.53845","article-title":"Guillain-Barr\u00e9 syndrome following COVID-19 vaccination in the United States \u2013 Reports to the vaccine adverse event reporting system","volume":"6","author":"Abara","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.023_b0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the vaccine safety datalink","volume":"5","author":"Hanson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"40","key":"10.1016\/j.vaccine.2023.06.023_b0150","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.15585\/mmwr.mm6940e1","article-title":"Case Series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection - United Kingdom and United States, March-August 2020","volume":"69","author":"Morris","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"31","key":"10.1016\/j.vaccine.2023.06.023_b0155","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2020.05.064","article-title":"Consensus summary report for CEPI\/BC March 12\u201313, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines","volume":"38","author":"Lambert","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.023_b0160","article-title":"Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis","volume":"370","author":"Allotey","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.023_b0165","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/AOG.0000000000004339","article-title":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19)","volume":"137","author":"Metz","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.023_b0170","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/AOG.0000000000004025","article-title":"Characteristics and outcomes of 241 births to women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at Five New York City Medical Centers","volume":"136","author":"Khoury","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.06.023_b0175","unstructured":"American College of Obstetricians and Gynecologists. COVID-19 vaccination considerations for obstetric\u2013gynecologic care. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care [accessed 3\/30\/2023]."},{"key":"10.1016\/j.vaccine.2023.06.023_b0180","unstructured":"Society for Maternal and Fetal Medicine. COVID-19 vaccination if you are pregnant or breastfeeding. https:\/\/s3.amazonaws.com\/cdn.smfm.org\/media\/3040\/COVID_vaccine__Patients_JULY_29_2021_final.pdf [accessed 3\/30\/2023]."},{"key":"10.1016\/j.vaccine.2023.06.023_b0185","first-page":"1","article-title":"Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs","volume":"Vol. 6","author":"Weber","year":"1984"},{"issue":"6","key":"10.1016\/j.vaccine.2023.06.023_b0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in US infants","volume":"370","author":"Yih","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.023_b0195","unstructured":"FDA Biologics Effectiveness and Safety System https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/cber-biologics-effectiveness-and-safety-best-system [accessed 3\/30\/2023]."},{"key":"10.1016\/j.vaccine.2023.06.023_b0200","unstructured":"Medicare program \u2013 general information. https:\/\/www.cms.gov\/medicare\/medicare-general-information\/medicaregeninfo [accessed 3\/30\/2023]."},{"key":"10.1016\/j.vaccine.2023.06.023_b0205","unstructured":"Vaccine Safety Datalink. https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html [accessed 3\/30\/2023]."},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.023_b0210","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15585\/mmwr.mm7103a4","article-title":"Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices - United States, December 2021","volume":"71","author":"Oliver","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.06.023_b0215","unstructured":"FDA memo: CBER recommendation to revise the Emergency Use Authorization for the Janssen COVID-19 Vaccine to limit the authorized use to individuals 18 years of age and older for whom other FDA-authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine. https:\/\/www.fda.gov\/media\/158318\/download [accessed 3\/30\/2023]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:41Z","timestamp":1759404461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23006874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":43,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0264410X23006874"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021\u2013February 2022","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}